ST. HELIER, Jersey — — Novocure, a commercial stage oncology company, announced today that the first patient has been enrolled in the STELLAR trial, an open-label, single-arm Phase II trial of Tumor Treating Fields together with pemetrexed and cisplatin or carboplatin in patients with newly diagnosed, unresectable malignant mesothelioma. STELLAR is anticipated to enroll 80 patients from Germany, Italy and Poland.
